**Table 3.** Summary of objective best response in patients with relapsed or refractory Ewing sarcoma and osteosarcoma treated with a combination of cabozantinib, topotecan and cyclophosphamide (n=12).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Total Patients** (n=12)  **n (%)** | **Ewing Sarcoma** (n=7)  **n (%)** | **Osteosarcoma** (n=5)  **n (%)** |
| Objective best response |  |  |  |
| Complete response | 0 | 0 | 0 |
| Partial response | 1 (8.3) | 1 (14.3) | 0 |
| Stable disease\* | 7 (58.3) | 4 (57.1) | 3 (60) |
| Progressive disease | 2 (16.7) | 2 (28.6) | 0 |
| Unknown | 2 (16.7) | 0 | 2 (40) |
| Response Rate | 1/12 [8.3%; 95% CI 0.21-38%] | 1/7 [14.3%; 95% CI 0.36-58%] | 0/5 [0%; 95% CI 0-52%] |

\*Stable disease includes three patients with RECIST non-measurable disease with Non-CR/non-PD.

CI = Confidence interval